Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29517913 | 0.78 | IDO1 (0.53) | IDO1TSHRADRA2AADRA1ALMNA | |
| SCHEMBL12928463 | 0.78 | IDO1 (0.53) | IDO1TSHRADRA2AADRA1ALMNA | |
| SCHEMBL15004316 | 0.78 | IDO1 (0.53) | IDO1TSHRADRA2AADRA1ALMNA | |
| SCHEMBL29357487 | 0.77 | IDO1 (0.57) | IDO1TSHRADRA2AADRA1ALMNA | |
| SCHEMBL145977 | 0.77 | IDO1 (0.57) | IDO1TSHRADRA2AADRA1ALMNA | |
| SCHEMBL7898127 | 0.77 | IDO1 (0.52) | IDO1 | |
| SCHEMBL1705441 | 0.77 | IDO1 (0.52) | IDO1TSHRADRA2AADRA1ALMNA | |
| SCHEMBL13082165 | 0.76 | IDO1 (0.55) | IDO1TSHRADRA2AADRA1ALMNA | |
| SCHEMBL5541899 | 0.75 | CYP19A1 (0.54) | — | |
| SCHEMBL15147106 | 0.74 | IDO1 (0.53) | IDO1TSHRADRA2AADRA1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153836-B2 | Silsesquioxane compound mixture, hydrolyzable silane compound, making methods, resist composition, patterning process, and substrate processing | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20080311514-A1 | SILSESQUIOXANE COMPOUND MIXTURE, HYDROLYZABLE SILANE COMPOUND, MAKING METHODS, RESIST COMPOSITION, PATTERNING PROCESS, AND SUBSTRATE PROCESSING | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311514-A1 | SILSESQUIOXANE COMPOUND MIXTURE, HYDROLYZABLE SILANE COMPOUND, MAKING METHODS, RESIST COMPOSITION, PATTERNING PROCESS, AND SUBSTRATE PROCESSING | STS, LSS, SRMS | IDO1 2371/4885TSHR 4804/4885ADRA2A 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.